Clinical management of patients receiving cell-based immunoregulatory therapy.
Administering immunoregulatory cells as medicinal agents is a revolutionary approach to the treatment of immunologically mediated diseases. Isolating, propagating, and modifying cells before applying them to patients allows complementation of specific cellular functions, which opens astonishing new possibilities for gain-of-function antigen-specific treatments in autoimmunity, chronic inflammatory disorders, and transplantation. This critical review presents a systematic assessment of the potential clinical risks posed by cell-based immunotherapy, focusing on treatment of renal transplant recipients with regulatory macrophages as a concrete example.
Department of Surgery, Experimental Surgery Division, University Hospital Regensburg, Regensburg, Germany.
James A
JA
Hutchinson
Norbert
N
Ahrens
Paloma
P
Riquelme
Lisa
L
Walter
Michael
M
Gruber
Carsten A
CA
Böger
Stefan
S
Farkas
Marcus N
MN
Scherer
Christiane
C
Broichhausen
Thomas
T
Bein
Hans-J
HJ
Schlitt
Fred
F
Fändrich
Bernhard
B
Banas
Edward K
EK
Geissler
D006084:Graft Rejection; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods*; D016030:Kidney Transplantation
D007166:Immunosuppressive Agents